Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Mélanie Héroult

Ulf Bömer

Klemens Lustig

Bernd Buchmann

Walter Hübsch

Niels Lindner

Hartmut Schirok

Joachim Telser

Mario Lobell

Michael Härter

Dirk Brohm

Antje Kahnert

Marie-Pierre Collin

Hannah Jörißen

Sylvia Grünewald

Verena Vöhringer

Verena Voehringer

Frank Süßmeier

Ulf BÖMER

This invention relates to novel substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-fJ[1,2,4]triazin-4-amine derivatives having protein tyrosine kinase inhibitory activities, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating proliferative disorders, in particular cancer and tumor diseases. 

Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment cancer

This invention relates to novel substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives having protein tyrosine kinase inhibitory activities, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating proliferative disorders, in particular cancer and tumor diseases.

Substituted benzothienyl-pyrrolotriazines and uses thereof

Growing community of inventors

Berlin, Germany

Mélanie Héroult